Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary, Pearsanta Inc., has submitted a proposal for the Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs (“CDMRP”) of the Department of Defense. According to the announcement, the proposal is designed to validate a novel assay based on Pearsanta’s proprietary Mitomic(R) technology designed for the early detection of ovarian cancer.
“We believe the clinical impact of Pearsanta’s Mitomic Ovarian Test could be profound,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “If we are successful in facilitating earlier detection and more effective treatment interventions through a simple blood test, we believe that we can significantly improve survival rates for women with ovarian cancer, addressing a critical unmet need in women’s health. Despite the high incidence and mortality rates, we are not aware that any blood tests are currently available with adequate sensitivity for early ovarian cancer detection. Our acceleration of Pearsanta’s innovations seeks to address a critical unmet need in women’s health and can potentially save many lives.”
To view the full press release, visit https://ibn.fm/sLvFQ
About Aditxt Inc.
Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, including Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies. Adivir(TM) Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta(TM) Inc. delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia. For more information, please visit www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN